Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Lung Diseases 1Colonic Neoplasms 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 9Pemetrexed 7pembrolizumab 4osimertinib 3entinostat 3Gemcitabine 3zipalertinib 2selpercatinib 2pralsetinib 2durvalumab 2camrelizumab 2Paclitaxel 2Erlotinib Hydrochloride 2Cisplatin 2Bronchoscopy 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1ficlatuzumab 1exemestane 1demcizumab 1cobimetinib 1ceralasertib 1atezolizumab 1alectinib 1aflibercept 1Vinorelbine 1Toll-Like Receptor 1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lung Diseases × TNFSF10 protein, human × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡